Bonsignore Gregorio, Ranzato Elia, Martinotti Simona
DiSIT- Dipartimento di Scienze e Innovazione Tecnologica, University of Piemonte Orientale, Viale Teresa Michel 11, 15121, Alessandria, Italy.
Laboratorio Integrato di Ricerca Preclinica, AOU "SS Antonio E Biagio e Cesare Arrigo", Via Venezia 16, 15121, Alessandria, Italy.
Invest New Drugs. 2025 May 8. doi: 10.1007/s10637-025-01540-9.
Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body's serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM's prevalence. PM has a long latency period, making major surgery ineffective and necessitating systemic treatment. Despite the progress of mesothelioma treatment, the median survival is very poor; so, there is a strong need to explore new therapeutic approaches. This study explores the use of BOLD-100, a novel therapeutic drug that targets GRP78, a protein overexpressed in PM cells. BOLD-100, a ruthenium-based small molecule therapeutic drug, is being investigated for the treatment of advanced gastrointestinal malignancies in conjunction with chemotherapy. Our aim is to investigate cellular responses of several PM cell lines to a regimen that includes BOLD-100 in addition to other commonly used treatments. BOLD-100 is a ruthenium-based anticancer therapeutic.
胸膜间皮瘤（PM）是一种罕见的癌症，影响身体浆膜表面的胸膜层。接触石棉纤维（一种具有绝缘特性的天然纤维材料）是PM发病的原因之一。PM的潜伏期很长，这使得大手术无效，因此需要进行全身治疗。尽管间皮瘤治疗取得了进展，但中位生存期仍然很差；所以，迫切需要探索新的治疗方法。本研究探讨了BOLD-100的使用，BOLD-100是一种新型治疗药物，靶向在PM细胞中过表达的GRP78蛋白。BOLD-100是一种基于钌的小分子治疗药物，正在与化疗联合用于治疗晚期胃肠道恶性肿瘤的研究。我们的目的是研究几种PM细胞系对包括BOLD-100以及其他常用治疗方法的方案的细胞反应。BOLD-100是一种基于钌的抗癌治疗药物。
